Institutional Investors Negative on on Tetraphase Pharmaceuticals Inc Falls

June 14, 2018 - By Harriett Tippett

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Logo

Sentiment for Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) institutional sentiment decreased to 1.05 in Q1 2018. Its down -0.14, from 1.19 in 2017Q4. The ratio fall, as 40 institutional investors increased or started new holdings, while 38 reduced and sold stock positions in Tetraphase Pharmaceuticals Inc. The institutional investors in our partner’s database now possess: 19.93 million shares, down from 29.51 million shares in 2017Q4. Also, the number of institutional investors holding Tetraphase Pharmaceuticals Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 23 Increased: 27 New Position: 13.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $219.43 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

The stock increased 6.78% or $0.27 during the last trading session, reaching $4.25. About 1.70 million shares traded or 120.28% up from the average. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has declined 48.55% since June 14, 2017 and is downtrending. It has underperformed by 61.12% the S&P500.

Analysts await Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report earnings on August, 1. They expect $-0.36 EPS, up 56.63 % or $0.47 from last year’s $-0.83 per share. After $-0.42 actual EPS reported by Tetraphase Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -14.29 % EPS growth.

Broadfin Capital Llc holds 0.5% of its portfolio in Tetraphase Pharmaceuticals, Inc. for 1.05 million shares. 683 Capital Management Llc owns 600,000 shares or 0.16% of their US portfolio. Moreover, Tekla Capital Management Llc has 0.1% invested in the company for 859,322 shares. The Michigan-based Dow Chemical Co De has invested 0.07% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 262,896 shares.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $98,932 activity.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Ratings analysis reveals 83% of Tetraphase Pharmaceutical’s analysts are positive. Out of 6 Wall Street analysts rating Tetraphase Pharmaceutical, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $3 while the high is $11. The stock’s average target of $7.20 is 69.41% above today’s ($4.25) share price. TTPH was included in 12 notes of analysts from February 12, 2018. The stock has “Buy” rating by Gabelli on Thursday, March 29. As per Monday, June 4, the company rating was maintained by FBR Capital. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Market Perform” rating by BMO Capital Markets on Thursday, March 8. FBR Capital maintained it with “Buy” rating and $6.0 target in Tuesday, February 27 report. On Wednesday, February 14 the stock rating was maintained by SunTrust with “Buy”. The rating was maintained by FBR Capital with “Buy” on Wednesday, March 7. The firm has “Buy” rating given on Monday, June 11 by FBR Capital. BMO Capital Markets downgraded the shares of TTPH in report on Wednesday, February 14 to “Market Perform” rating. As per Monday, February 12, the company rating was initiated by FBR Capital. FBR Capital maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Wednesday, February 21 with “Buy” rating.

More notable recent Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news were published by: Benzinga.com which released: “21 Stocks Moving In Monday’s Pre-Market Session” on June 11, 2018, also Seekingalpha.com with their article: “Everest Medicines submits IND application to China for eravacycline in cIAI” published on June 04, 2018, Nasdaq.com published: “Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018” on May 21, 2018. More interesting news about Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) were released by: Seekingalpha.com and their article: “Achaogen: Buy Before The June 25 PDUFA Date” published on May 24, 2018 as well as Seekingalpha.com‘s news article titled: “Tetraphase Pharma’s eravacycline shows positive effect in late-stage studies; shares up 6% premarket” with publication date: June 11, 2018.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: